Lacotte L, Thierry A, Delwail V, Dreyfus B, Guilhot F
Department of Hematology and Clinical Oncology, CHU La Miletrie, Poitiers, France.
Acta Haematol. 2000;102(3):160-2. doi: 10.1159/000040993.
Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome have recently been observed in patients undergoing interferon alpha (IFN-alpha) therapy. However, the relationship between disease and therapy has not been established, essentially because of concomitant treatment or previous bone marrow transplantation. We present a case of TTP developing during IFN-alpha therapy for chronic myelogenous leukemia. In this case, IFN-alpha seems to be the only etiological agent.
近期，接受α干扰素（IFN-α）治疗的患者中观察到血栓性血小板减少性紫癜（TTP）和溶血尿毒综合征。然而，由于存在联合治疗或既往骨髓移植情况，疾病与治疗之间的关系尚未明确。我们报告1例在IFN-α治疗慢性粒细胞白血病期间发生TTP的病例。在该病例中，IFN-α似乎是唯一的病因。
